Taxol in the Management of Cancers of the Breast and the Ovary

References

• Harris J, Morrow R. M, Bonadonna G. Cancer of the breast. Cancer: Principles and Practice of Oncology, 4th ed., J R DeVita, S Hellman, S A Rosenberg. Lippincott, Philadelphia 1993; 1264–1272
   Google Scholar
• Holmes F, Walters R S, Theriault R L, et al. Phase II trial of Taxol, and active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797, abstract
   PubMed Web of Science ®Google Scholar
• Reichman B S, Seidman A D, Crown J PA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1943; 11: 1993, abstract
   Google Scholar
• Vermorken J B, Huizing M T, Liefting A JM, et al. High-dose Taxol (HDT) with G-CSF in patients with advanced breast cancer (ABC) refractory to anthracycline (ANT) therapy. Eur J Cancer 1993; 29A: 83, abstract
   Google Scholar
• Nabholtz J M, Gelmon Botenbal K. M, et al. Randomized trial of two doses of Taxol in metastatic breast cancer. Proc Am Soc Clin Oncol 1993; 12: 60, abstract
   Google Scholar
• Seidman Paclitaxel A. the long and short of it. Cancer J Sci Am 1995; 1: 250–251
   PubMedGoogle Scholar
• Rowinsky E K, Donehower R, Paclitaxel C. N Engl J Med 1995; 332: 1004–1014, Taxol
   PubMed Web of Science ®Google Scholar
• Nabholtz J, Gelmon M. K, Bontenbal M, et al. Multicenter randomised comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858–1867
   PubMed Web of Science ®Google Scholar
• Winner E, Berry D, Duggan D, et al. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342. Am Soc Clin Oncol I 1998; 7: 101a, abstract
   Google Scholar
• Peretz T, Sulkes A, Chollet P, et al. A multicenter. randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer 1995; 31A(Suppl 5)S75, abstract
   Google Scholar
• Mamounas E, Brown A, Smith R, et al. Effect of taxol duration of infusion in advanced breast cancer (ABC) results from NSABP B-26 trial comparing 3- to 24-hr infusion of high-dose taxol. Am Soc Clin Oncol 1998; 17: 101a, abstract
   Google Scholar
• Holmes F A, Valero V, Buzdar A U, et al. Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer (MBC). Am Soc Clin Oncol 1998; 17: 110a, abstract
   Google Scholar
• Lopes N M, Adams E F, Pitts T W, et al. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 234–242
   Google Scholar
• Liebmann J E, Cook J A, Lipschultz C, et al. Cytotoxic studies of paclitaxel in human tumor cell lines. Br J Cancer 1993; 68: 1104–1109
   PubMed Web of Science ®Google Scholar
• Wu-Wong J, Chiou W, Han E, et al. Effects of paclitaxel on cell proliferation, apoptosis and angiogenesis. Proc Am Assoc Cancer Res 1997; 38: 531 , abstract
   Google Scholar
• Torres K E, Castillo G, Horwitz S B. Induction of apoptosis by low concentrations of Taxol is not dependent on a G2/M block. Proc Am Assoc Cancer Res 1997; 38: 530, abstract
   Google Scholar
• Seidman A D. One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index. 1998; 12(Suppl 1)19–22
   Google Scholar
• Chang A Y, Boros L, Asbury R, et al. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin Oncol 1997; 24(Suppl 17)S17-44–S17-47
   Google Scholar
• Lau D H, Young L, Xue L, et al. Paclitaxel: an ongoing antagonist in a metastatic breast cancer model. Am Soc Clin Oncol 1998; 17: 107a, abstract
   Google Scholar
• Seidman A D, Murphy B, Hudis C, et al. Activity of Taxol® (T) by weekly 1 hour infusion in patients (pts) with metastatic breast cancer (MBC): a phase II and pharmacologic study. Am Soc Clin Oncol 1997; 16: 148a, abstract
   Google Scholar
• Sikov W, Akerley W, Strenger R, et al. Weekly high-dose paclitaxel (P) demonstrates significant activity in advanced breast cancer (BC). Am Soc Clin Oncol 1998; 17: 112a, abstract
   Google Scholar
• Henderson I C. Chemotherapy for metastatic disease. Breast Disease, 2nd ed., J R Harris, S Hellman, J C Henderson, et al. Lippincott, Philadelphia 1991; 604–665
   Google Scholar
• Reichman B, Seidman A, Crown J, et al. Paclitaxel and recombinant human granulocyte colony stimulating factor as initial therapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943–1951
   PubMed Web of Science ®Google Scholar
• Wilson W, Berg S, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer. A phase I/ II trial of 96-hour infusion. J Clin Oncoi 1994; 12: 1621–1629
   Web of Science ®Google Scholar
• Sledge G W, Neuberg D, Ingle J, et al. Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Am Soc Clin Oncol 1997; 16: 1a, abstract
   Google Scholar
• Gamucci T, Piccart M, Brüning P, et al. Single agent taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC). Final results of an EORTC randomized study with crossover. Am Soc Clin Oncol 1998; 17: la, 11(abstract)
   Google Scholar
• Fischerman J S, McCahe M, Noone M, et al. Phase I study of Taxol, doxorubicin plus granulocyte colony-stimulating factor in patients with metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 189–194
   PubMedGoogle Scholar
• Sledge G W, Robert N, Sparano J A, et al. Paclitaxel (Taxol)/ doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 1994; 21: 15–18
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688–2699
   PubMed Web of Science ®Google Scholar
• Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687–693
   PubMed Web of Science ®Google Scholar
• Gianni L, Capri G, Tarenzi E, et al. Efficacy and cardiac effects of 3-hour paclitaxel plus bolus doxorubicin in women with untreated metastatic breast carcinoma. Proc Am Soc Clin Oncol 1996; 15: 116, abstract
   Google Scholar
• Schwartsmann G, Menke C H, Caleffi M, et al. Phase II trial of Taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Am Soc Clin Oncol 1996; 15: 126, abstract
   Google Scholar
• Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function following combination therapy with taxol® (T) and doxorubicin α for advanced breast cancer (ABC). Am Soc Clin Oncol 1998; 17: 115a, abstract
   Google Scholar
• Praga C, Trave F, Petroccione A. Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. Clinical Measurements in Drug Evaluation, W S Nimmo, G T Tucker. Wolfe Publishing, LondonUK 1991; 131–142
   Google Scholar
• Dombernowsky P, Boegaard M, Andersen E, et al. Doxorubicin plus paclitaxel in advanced breast cancer. Semin Oncol 1997; 24(Suppl 17)S17-15–S17-18
   Google Scholar
• Frassineti G L, Zoli W, Silvestro L, et al. Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin Oncol 1997; 24(Suppl 17)S17-19–S17-25
   Google Scholar
• Luck H J, Thomssen C, du Bois A, et al. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semin Oncol 1997; 24(Suppl 17)S17-35–S17-39
   Google Scholar
• Carmichael J, Jones A, Hutchison T. A phase II trial of epirubicin plus paciitaxel in metastatic breast cancer. Semin Oncol 1997; 24(Suppl 17)S17-44–S17-47
   Google Scholar
• Conte P F, Gennari A, Salvadori B, et al. Paclitaxel plus epirubicin in advanced breast cancer. Oncology 1998; 12(Suppl l)40–44
   PubMedGoogle Scholar
• Tolcher A W. Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 1996; 23(Suppl 1)37, abstract
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Armstrong D, Donehower R, et al. The hematologic toxicity of the Taxol/Cytoxan doublet is sequence-dependent. Proc Am Soc Clin Oncol 1994; 13: 74, abstract
   Google Scholar
• Sessa C, Pagani O, Parma G, et al. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer. Semin Oncol 1995; 22(Suppl 6)112, abstract
   PubMedGoogle Scholar
• Fields K K, Partyka J S, Perkins J B, et al. Cyclophosphamide and Taxol® is an active salvage regimen in patients with anthracycline refractory metastatic breast cancer. Proc Am Soc Clin Oncol 1997; 16: 168a, abstract
   Google Scholar
• Hortobagyi G N, Ibrahim N. Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol 1996; 23(Suppl 1)53, abstract
   PubMed Web of Science ®Google Scholar
• Weiselberg L, Budman D R, O'Mara V, et al. Phase I trial of sequential vinorelbine-paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy. Proc Am Soc Clin Oncol 1996; 15: A54, abstract
   Google Scholar
• Michelotti A, Gennari A, Salvadori B, et al. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Semin Oncol 1996; 23(Suppl 1)38, abstract
   PubMedGoogle Scholar
• Vici P, Amodio A, Di Lauro L, et al. Simultaneous infusion of vinorelbine (VNB) and paclitaxel (P) as first-line chemotherapy (CT) in advanced breast cancer (ABC) patients (patients). Proc Am Soc Clin Oncol 1997; 16: 196a, abstract
   Google Scholar
• Chang A Y, Garrow G C. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 1995; 22(Suppl 5)66, abstract
   PubMedGoogle Scholar
• Jaremtchuk A, Matwiejuk M, Polera O, et al. Feasibility study of the combination of Navelbine® and paclitaxel (PCL) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1997; 16: 175a, abstract
   Google Scholar
• Romero Acuña L, Langhi M, Pérez J, et al. Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1997; 16: 188a, abstract
   Google Scholar
• Martin M, Casado A, Segura P P, et al. Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines. Oncology 1998; 12(Suppl 1)28–30
   PubMed Web of Science ®Google Scholar
• Paul D M, Garett A M, Meshad M, et al. Paclitaxel and 5Fluorouracil in metastatic breast cancer: The US experience. Semin Oncol 1996; 23(Suppl 1)48, abstract
   PubMed Web of Science ®Google Scholar
• Zaniboni A, Guarinoni L, Distefano L, et al. Taxol, folinic acid and fluoruouracil (TAFF) as second-line treatment for advanced breast cancer (ABC) (Meeting abstract). Proc Am Soc Clin Oncol 1996; 15: A202, abstract
   Google Scholar
• Fornasreio A, Ghiotto C, Daniele O, et al. Paclitaxel (Tax) + Fluorouracil (Fu): phase I/II study in metastatic breast cancer (MBC). Breast Cancer Res Treat 1996; 37(Suppl)302, abstract
   Google Scholar
• Elkordy M, Matters L, Coniglio D, et al. The effect of continuous infusion 5-FU (CI-F) with or without taxol (T) as induction therapy in stade IV breast carcinoma (BC) (Meeting abstract). Proc Am Soc Clin Oncol 1994; 13: A184, abstract
   Google Scholar
• Madajewicz S, LiPera W, Pendyala L, et al. Phase I study of 96 hr continuous intravenous infusion (CI) of taxol (T) followed by 24 hr CI of 5-fiuorouracil (5-FU) and folinic acid (FA) (Meeting abstract). Proc Am Soc Clin Oncol 1995; 14: A1589
   Google Scholar
• Gleissner A, Hellmann A, Koldehoff M, et al. Phase I study of paclitaxel and 5-fluorouracil as second-line therapy in patients with metastatic breast cancer. Breast Cancer Res Treat 1996; 37(Suppl)312, abstract
   Google Scholar
• Takimoto C H, Morrison G B, Frame J N, et al. A phase I and pharmacologic trial of paclitaxel (Taxol®) and 5-fluorouracil (5-FU) plus leucovorin (LCV) in patients with solid tumors. Proc Am Soc Clin Oncol 1995; 14: 471, abstract
   Google Scholar
• Klaassen U, Harstrick A, Wilke H, et al. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/ folinic acid in the treatment of metastatic breast cancer. Semin Oncol 1996; 23(Suppl 1)44, abstract
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Jones S E, Erland J B, et al. Paclitaxel, mitoxantrone, 5-fluorouracil, and high dose leucovorin (P-NFL) in the the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14: A64, abstract
   Google Scholar
• Klaassen U, Wilke H, Müler C H, et al. Weekly high-dose 24-hour infusional 5-FU plus leucovorin (HD5-FD/LV) in combination with paclitaxel (P) and cisplatin (C) in the first-line treatment of metastatic breast cancer (MBC): results of a phase II study. Proc Am Soc Clin Oncol 1997; 16: 177a, abstract
   Google Scholar
• Sledge G W, Loehrer P J, Roth B J, et al. Cisplatin as first-line therapy therapy for metastatic breast cancer. J Clin Oncol 1988; 6: 1811–1814
   PubMed Web of Science ®Google Scholar
• Smith I E, Talbot D C. Cisplatin and its analogues in the treatment of advanced breast cancer. A review. Br J Cancer 1992; 65: 787–793
   PubMed Web of Science ®Google Scholar
• Berry J, Ezzat A, El-Warith A, et al. Sequential taxol/platinum: pilot study in metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14: 136, abstract
   Google Scholar
• Ezzat A, Rahal M, Baearbashi S, et al. Pathological response (CpR) induced by circadian Taxol® (T) and cis-platinum (P) in locally advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1997; 16: 168a, abstract
   Google Scholar
• Gelmont K A, O'Reilly S E, Tolcher A W, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14: 1185, abstract
   PubMed Web of Science ®Google Scholar
• McCaskill-Stevens W J, Fox S, Harlan J, et al. Phase I/II study of biweekly paclitaxel (P) and carboplatin (C) in the treatment of patients (patients) with stage IV breast carcinoma. Proc Am Soc Clin Oncol 1997; 183a, abstract
   Google Scholar
• Aravantinos G, Athanassiades A, et al. Combination of carboplatin and paclitaxel in anthracyline-resistant advanced breast cancer (ABC). A Hellenic Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 1997; 16: 168a, A Hellenic Cooperative Oncology Group Study abstract
   Google Scholar
• Demetri G, Berry D, Norton L, et al. Clinical outcomes of node positive breast cancer patients treated with dose-intensified adryamycin/cyclophosphamide followed by Taxol as adjuvant systemic chemotherapy in (CALGB9141). Proc Am Soc Clin Oncol 1997; 16: 143a, abstract
   Google Scholar
• Henderson 1 C, Berry D, Demetri G, et al. Improved disease-free (DPS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin α dose level in the adjuvant chemotherapy of patients (patients) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 1998; 17: 101a, abstract
   Google Scholar
• Hudis C A. Dose-dense paclitaxel-containing adjuvant therapy for breast cancer. Oncology 1998; 12(Suppl 1)16–18
   PubMed Web of Science ®Google Scholar
• Anelli A, Albuquerque A D, Tabacof J, et al. Paclitaxel and doxorubicin as neoadjuvant chemotherapy in locally advanced breast cancer—preliminary results. Proc Am Soc Clin Oncol 1997; 16: 158a, abstract
   Google Scholar
• Schwartzberg L S, Birch R, Weaver C H, et al. High pathological complete response (CR) rate to sequential doxorubicin and paclitaxel primary chemotherapy for locally advanced breast cancer (LABC). Am Soc Clin Oncol 1998; 17: 112a, abstract
   Google Scholar
• Slamon D, Leyland-Iones B, Shak S, et al. Addition of Herceptin(tm) (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer multinational controlled phase III trial. Am Soc Clin Oncol 1998; 17: 98a, abstract
   Google Scholar
• Wiernik P H, Schwartz E L, Strauman J J, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486–2493
   PubMed Web of Science ®Google Scholar
• Donehower R C, Rowinsky E K, Grochow L B, et al. Phase I trial of taxol in patients with advanced cancer author. Cancer Treat Rep 1987; 71: 1171–1177
   PubMedGoogle Scholar
• Einzig A l, Wiernik P H, Sasloff I, et al. Phase II study and long term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748–1753
   PubMed Web of Science ®Google Scholar
• McGuire W P, Rowinsky E K, Rosenheim N B, et al. Taxol: A unique antineoplastic agent with significant activity in advanced epithelial neoplasm. Ann Intern Med 1989; 11: 273–279
   Google Scholar
• Thigpen T, Blessing J, Ball H, et al. Phase II trial of Taxol as second line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12: 1748–1753
   PubMed Web of Science ®Google Scholar
• Athanassiou A, Pectasides D, Vathalitis I, et al. Taxol patients with cisplatin or carboplatin refractory ovarian carcinoma. Proc Am Soc Clin Oncol 1994; 13: A870, abstract
   Google Scholar
• Mendiola C, Garcia-Ribas I, Cubedo R, et al. High response rate of taxol in platinum pretreated advanced ovarian cancer. Proc Am Soc Clin Oncol 1995; 16: A1276, abstract
   Google Scholar
• Aravantinos G, Skarlos D V, Kosmidis P, et al. A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. Eur J Cancer 1997; 33: 160–163
   PubMed Web of Science ®Google Scholar
• Blorn R, Palm N, Simonsen E. Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy. Acta Oncol 1996; 35: 733–736
   PubMed Web of Science ®Google Scholar
• Du Bois A, Luck H J, Buser K, et al. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. Eur J Cancer 1997; 33: 379–384
   PubMed Web of Science ®Google Scholar
• Nardi M, Aloe A, De Marco S, et al. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol 1997; 20: 230–232
   PubMed Web of Science ®Google Scholar
• Noda K, Ikeda M, Kudo R, et al. Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion. Can To Kagaku Ryoho 1996; 23: 317–325
   PubMedGoogle Scholar
• Phillips K A, Friedlander M, Olver I, et al. Australasian multicenter phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Aust N Z J Med 1995; 25: 337–343
   PubMedGoogle Scholar
• Trimble E L, Adamas J D, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to national cancer institute treatment referral center 9103. J Clin Oncol 1993; 11: 2405–2410
   PubMed Web of Science ®Google Scholar
• Gore M E, Levy V, Rustin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Royal Marsden NHS Trust, London, UK. Br J Cancer 1995; 72: 1016–1019
   PubMed Web of Science ®Google Scholar
• Eisenhauer E A, Ten Bokkel Huinink WW, Swenerton K D, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–2666
   PubMed Web of Science ®Google Scholar
• Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187–192
   PubMed Web of Science ®Google Scholar
• Löffler T M, Freund W, Lipke J, et al. Schedule and dose-intensified paclitaxel as weekly 1 -hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 1996; 23: 32–34
   PubMed Web of Science ®Google Scholar
• Breier S, Lebedinsky C, Pelayes L, et al. Phase I/II weekly paclitaxel (P) 80 mg/m2 in pretreated patients with breast and ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: A568, abstract
   Google Scholar
• Raymond E, Hanauske A, Faivre S, et al. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anticancer Drugs 1997; 8: 379–385
   PubMed Web of Science ®Google Scholar
• Markman M, Rose P G, Jones E, et al. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 1998; 16: 1849–1851
   PubMed Web of Science ®Google Scholar
• Soulie P, Trandafir L, Taamma A. Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer. Anticancer Drugs 1997; 8: 763–766
   PubMed Web of Science ®Google Scholar
• Goldberg J M, Piver M S, Hempling R E, et al. Paclitaxel and cis-platin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1996; 63: 312–317
   PubMed Web of Science ®Google Scholar
• Johnston C M, Pearl M L, Reynolds R K, et al. Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel. Eur J Gynaecol Oncol 1995; 16: 439–447
   PubMedGoogle Scholar
• Reed E, Kohn E C, Sarosy G, et al. Paclitaxel, cisplatin, cyclo-phosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 1995; 22: 90–96
   PubMed Web of Science ®Google Scholar
• Poole C, Perren T J, Jordan S D, et al. Sequential paclitaxel and cisplatin chemotherapy in patients with newly diagnosed epithelial ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: A1271
   Google Scholar
• Bolis G. Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Semin Oncol 1995; 22: 32–34
   PubMed Web of Science ®Google Scholar
• Bolis G, Scarf one G, Villa A, et al. A phase I trial with fixed-dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer. Semin Oncol 1997; 24: 25, abstract
   Google Scholar
• Martoni A, Zamagni C, Gentile A, et al. A phase I study of paclitaxel and carboplatin as first line chemotherapy in stage III-IV ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: A860, abstract
   Google Scholar
• Meerpohl H G, du Bois A, Kühnle H, et al. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. Semin Oncol 1995; 22: 7–12
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Veenhof C, Helmerhorst T, et al. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 1995; 22: 97–100
   PubMed Web of Science ®Google Scholar
• Huizing M T, van Warmerdam L J, Rosing H. A phase I and phar-macologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1997; 15: 1953–1964
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck H J, Bauknecht T, et al. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 1997; 8: 355–361
   PubMed Web of Science ®Google Scholar
• McGuire W P, Hoskins W J, Brady M F, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 4–6
   Google Scholar
• Muggia F M, Brady P S, Brady M F, et al. Phase III of cisplatin or paclitaxel versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132. Proc Am Soc Clin Oncol 1997; 16: A1257, abstract
   Google Scholar
• Calvert A H, Boddy A, Bailey N P, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995; 22: 91–98
   PubMed Web of Science ®Google Scholar
• Guastalla J P, Pujade-Lauraine E, Weber B, et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann Oncol 1998; 9: 37–43
   PubMed Web of Science ®Google Scholar
• Neijt J P, Hansen M, Hansen S W, et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and pacli-taxel-carboplatin. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A1259, abstract
   Google Scholar
• Kohn E C, Sarosy G A, Davis P, et al. A pilot study of cyclophos-phamide (CTX), paclitaxel (T), and cisplatin (P) with G-CSF for newly diagnosed ovarian cancer patients. Proc Am Soc Clin Oncol 1996; 15: A757, abstract
   Google Scholar
• Coeffic D, Benhammouda A, Antoine E C, et al. Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophos-phamide in advanced ovarian carcinoma. Semin Oncol 1997; 24: S2-38–S2–40
   Google Scholar
• Young R C, Perez C A, Hoskins W J. Cancer of the ovary. Cancer: Principles and Practice of Oncology, V T De Vita, S Hellman, S A Rosenberg. J.B Lippincott, Philadelphia 1993; 1226–1263
   Google Scholar
• Miglietta L, Amoroso D, Bruzzone M, et al. Paclitaxel plus ifos-famide in advanced ovarian cancer: a multicenter phase II study. Oncology 1997; 54: 102–107
   PubMed Web of Science ®Google Scholar
• Bunnell C A, Thompson L, Buswell L, et al. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 1998; 82: 561–566
   PubMed Web of Science ®Google Scholar
• Veldhuis G J, Willemse P H, Beijnen J H, et al. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Br J Cancer 1997; 75: 703–709
   PubMed Web of Science ®Google Scholar
• Naumann R W, Alvarez R D, Omura G D, et al. A phase I study of paclitaxel and cisplatin with escalating doses of doxorubicin in patients with previously untreated epithelial ovarian cancer. Proc Am Soc Clin Oncol 1997; 16: A1333, abstract
   Google Scholar
• Romanini A, Tanganelli L, Galata M, et al. Epidoxorubicin, carboplatin and taxol in advanced epithelial ovarian cancer patients with residual disease more than 2 cm after surgery: a phase I study (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1997; 38: A1504, abstract
   Google Scholar
• Hill M E. G-CAT (GCSF, cis/carboplatin, adriamycin and Taxol) for advanced ovarian cancer: active but toxic. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A1321
   Google Scholar
• O'Reilly S, Fleming G F, Barker S D, et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15: 177–186
   PubMed Web of Science ®Google Scholar
• Piccart M J. Cisplatin/paclitaxel versus cisplatin/cyclophosphamide for advanced epithelial ovarian cancer: preliminary results from a large European-Canada intergroup trial. European Cancer Conference, Hamburg, 1987; 8–9
   Google Scholar